CC
RYTM icon

Checkpoint Capital’s Rhythm Pharmaceuticals RYTM Stock Holding History

Checkpoint Capital’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$132M Sell
1,186,000
-41,200
-3% -$3.73M 33.79% 1
2026
Q1 		$107M Buy
1,227,200
+235,000
+24% +$22.9M 38.3% 2
2025
Q4 		$106M Buy
992,200
+228,493
+30% +$24.2M 33.18% 2
2025
Q3 		$77.1M Sell
763,707
-296,293
-28% -$27.5M 25.84% 2
2025
Q2 		$67M Buy
1,060,000
+152,760
+17% +$9.35M 31.21% 2
2025
Q1 		$48.1M Buy
907,240
+179,258
+25% +$9.95M 26.37% 2
2024
Q4 		$40.8M Buy
727,982
+64,601
+10% +$3.57M 20.74% 2
2024
Q3 		$34.8M Sell
663,381
-258,719
-28% -$12.4M 17.24% 2
2024
Q2 		$37.9M Buy
922,100
+96,600
+12% +$3.86M 22.82% 1
2024
Q1 		$35.8M Buy
825,500
+95,500
+13% +$4.18M 23.91% 1
2023
Q4 		$33.6M Buy
+730,000
New +$23M 20.33% 1

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Checkpoint Capital's RYTM Position: Q2 2026 in Review

Checkpoint Capital reduced its Rhythm Pharmaceuticals (RYTM) stake by 3.4% in Q2 2026, selling an estimated $3.73M and leaving 1,186,000 shares worth $132M. The position accounts for 33.79% of the portfolio, ranked #1.

Checkpoint Capital first reported a position in RYTM in Q4 2023 and has held it in 11 quarters since. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Checkpoint Capital held 1,186,000 shares of Rhythm Pharmaceuticals worth $132M as of Q2 2026.
  • Checkpoint Capital sold 41,200 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $3.73M.
  • Rhythm Pharmaceuticals made up 33.79% of Checkpoint Capital's portfolio in Q2 2026, its #1 holding.
  • Checkpoint Capital first reported a position in Rhythm Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Checkpoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.